CourageAS is a joint venture between Couragene and the Foundation for Angelman Syndrome Therapeutics (FAST). We're committed to transforming the way Angelman Syndrome is treated. Our dedicated team is passionate about developing safe and effective therapies to improve the lives of those affected by this rare genetic disorder. At CourageAS, we believe in the power of courageous science to deliver hope and help to patients and their families.

Our mission is to advance the preclinical and clinical development of STEP-CRISPR for Angelman Syndrome.